reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
MUSA MURPHY USA INC.
MOS MOSAIC COMPANY
HNRG HALLADOR ENERGY CO.
HII HUNTINGTON INGALLS INDUSTRIES INC.
GT GOODYEAR TIRE & RUBBER COMPANY
FAST FASTENAL COMPANY
BGS B&G FOODS INC.
CNR. CANADIAN NATIONAL RAILWAY COMPANY
AGX ARGAN INC.
LEU CENTRUS ENERGY CORPORATION
GRPN GROUPON INC.
IPI INTREPID POTASH
SBTX SILVERBACK THERAPEUTICS
SDGR SCHRODINGER
RGC REGENCELL BIOSCIENCE HLDGS LTD
PPTA PERPETUA RESOURCES CORP
MPTI M TRON INDUSTRIES INC
ASPI ASP ISOTOPES INC
ANG ANGLOGOLD ASHANTI LIMITED
AZ A2Z CUST2MATE SOLUTIONS CORP
USAU US GOLD CORP
SLNO SOLENO THERAPEUTICS INC
BKTI BK TECHNOLOGIES CORP
Clene to Present at the Emerging Growth Conference
Clene to Present at the Emerging Growth Conference SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: April 17, 2025Time of Presentation: 12:00 p.m. EDTFormat: Corporate updat...
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-Worl...
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency - Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolution of the disease’s serious cardiovascular and musculoskeletal complications - - Findings highlight the urgent need for early and improved diagnosis, care and treatments that address the long-term systemic effects of ENPP1 Deficiency - BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative the...
Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-...
Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session Analyses of MRI and VEP data confirm anatomical and physiological improvements, indicating remyelination and neuronal repair in the brains of MS patients treated with CNM-Au8 during the long-term extension of VISIONARY-MSOver 90% of participants who showed improvements in cognition and vision also demonstrated corresponding improvements on MRI and visual electrophysiology tests SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Clene, Inc...
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
BPMC BLUEPRINT MEDICINES CORP.
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
PTGX PROTAGONIST THERAPEUTICS
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
GM GENERAL MOTORS COMPANY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
PINS PINTEREST INC. CLASS A
SWTX SPRINGWORKS THERAPEUTICS
SMCI SUPER MICRO COMPUTER
RVMD INC.
INZY REVOLUTION MEDICINES
TVTX INOZYME PHARMA
VRDN TRAVERE THERAPEUTICS INC
NUVB VIRIDIAN THERAPEUTICS INC
DAWN NUVATION BIO INC (A)
STX DAY ONE BIOPHARMACEUTICALS INC
GFS SEAGATE TECHNOLOGY HLDGS PLC
GMTX GLOBALFOUNDRIES INC
JANX GEMINI THERAPEUTICS INC
MLTX JANUX THERAPEUTICS INC
NUVL MOONLAKE IMMUNOTHERAPEUTICS
APGE NUVALENT INC
ORKA APOGEE THERAPEUTICS INC
ORUKA THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
BPMC BLUEPRINT MEDICINES CORP.
PTGX PROTAGONIST THERAPEUTICS
ARGX ARGENX ADS
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
SWTX SPRINGWORKS THERAPEUTICS
RVMD REVOLUTION MEDICINES
INZY INOZYME PHARMA
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
NUVL NUVALENT INC
APGE APOGEE THERAPEUTICS INC
Clene to Present at the Jones Healthcare and Technology Innovation Con...
Clene to Present at the Jones Healthcare and Technology Innovation Conference SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Jones Healthcare and Technology Innovation Conference and host 1x1 investor meetings. Date: Apr...
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healt...
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, from 2:15-2:55pm ET. A live webcast of the fireside chat can be...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
LOPE GRAND CANYON EDUCATION INC.
LNDC LANDEC CORP.
HOO HERBALIFE NUTRITION LTD.
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CAAS CHINA AUTOMOTIVE SYSTEMS ADS (N SHARES)
BFAM BRIGHT HORIZONS FAMILY SOLUTIONS INC.
AZO AUTOZONE INC.
ADMA ADMA BIOLOGICS INC
ACU ACME UNITED CORP.
OSTK OVERSTOCK.COM INC.
UVV UNIVERSAL CORP
FDP FRESH DEL MONTE PRODUCE INC.
TATT TAT TECHNOLOGIES LTD.
WMK WEIS MARKETS INC.
KINS KINGSTONE COS. INC.
NC NACCO INDUSTRIES INC. CL A
CHCI COMSTOCK HOLDING COMPANIES
VLGEA VILLAGE SUPER MARKET INC. CL A
LAUR LAUREATE EDUCATION INC. CLASS A
CMCL CALEDONIA MINING CORPORATION
ABT ABBOTT LABORATORIES
BRP BRP GROUP
GRPN GROUPON INC.
CNXC CONCENTRIX
DRVN DRIVEN BRANDS HOLDINGS
ALHC ALIGNMENT HEALTHCARE INC
ADSE ADS TEC ENERGY PLC
KLG_w WK KELLOGG CO
TRVG TRIVAGO N.V.
BG BUNGE LIMITED
IDR IDAHO STRATEGIC RESOURCES INC
DBD DIEBOLD NIXDORF INCORPORATED
CCB CHASE CAPITAL VIII CAP SEC H 8.25%
MNPR MONOPAR THERAPEUTICS INC.
AEVA AEVA TECHNOLOGIES INC.
ORLY OREILLY AUTOMOTIVE INC CDA
Clene Reports Full Year 2024 Financial Results and Recent Operating Hi...
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene planning to initiate the confirmatory Phase 3 RESTORE-ALS trial in subjects with ALS in mid-2025Secured new $10.0 million debt facility at a lower interest rate to replace remaining outstanding $7.85 million debt balance with Avenue Capital Cash, cash equivalents and marketable securities of $12.2 million as of December 31, 2024, includes $7.3 million in gross proceeds raised...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ATNI ATN INTERNATIONAL INC.
VZ VERIZON COMMUNICATIONS INC.
SYNL SYNALLOY CORP.
SCCO SOUTHERN COPPER CORPORATION
RGR STURM RUGER & COMPANY INC.
MRCY MERCURY SYSTEMS INC.
MKTX MARKETAXESS HOLDINGS INC.
KR KROGER CO.
FCX FREEPORT-MCMORAN INC.
EIG EMPLOYERS HOLDINGS INC.
DG DOLLAR GENERAL CORPORATION
CBOE CBOE GLOBAL MARKETS INC
ALL ALLSTATE CORPORATION
R1D AERCAP HOLDINGS NV
FNF FIDELITY NATIONAL FINANCIAL INC. - FNF GROUP
CNR. CANADIAN NATIONAL RAILWAY COMPANY
DGICA DONEGAL GROUP INC. CL A
LFVN LIFEVANTAGE
BRK.B BERKSHIRE HATHAWAY INC. CLASS B
HRTG HERITAGE INSURANCE HOLDINGS INC.
THG HANOVER INSURANCE GROUP INC.
FTG111 FLATEXDEGIRO AG
PAGS PAGSEGURO DIGITAL LTD
MGTX MEIRAGTX HOLDINGS PLC
OPRX OPTIMIZERX CORP
GRPN GROUPON INC.
RKT ROCKET COMPANIES
AVAH AVEANNA HEALTHCARE HLDGS INC
RGC REGENCELL BIOSCIENCE HLDGS LTD
QBTS D-WAVE QUANTUM INC.
ANG ANGLOGOLD ASHANTI LIMITED
METC RAMACO RESOURCES INC.
NXT NEXT GEOSOLUTIONS EUROPE S.P.A.
BNTC BENITEC BIOPHARMA INC
SARO STANDARDAERO INC.
ZBIO PROSHARES ULTRAPRO SHORT NASDAQ BIOTECHNOLOGY
USAU US GOLD CORP
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Tre...
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-regimen, post hoc analysis of long-term survival in HEALEY ALS Plat...
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces ...
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights - Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction, expected to support operations into the first quarter of 2026 - - Enrollment complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency; topline data expected in first quarter of 2026 - - Positive interim result...
- David Nierengarten
- Dennis Pak
- Martin Fan
Clene to Present at the 37TH Annual Roth Conference
Clene to Present at the 37TH Annual Roth Conference SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1x1 investor meetings. Date: March 18, 2025Time of Presentatio...
Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced D...
Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights DALLAS, March 03, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair drug testing, is proud to announce the launch of its innovative Quartile Reporting feature. This industry-first enhancement empowers organizations with unprecedented insights into drug test results, enabling data-driven decision-making and fostering safer, more productive workplaces. The new Quartile Reporting feature allows clients to see where a candidate’s or employee’s test results fall within a range o...
Clene and APST Enter Into an Agreement to Support FDA’s Recommendation...
Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkersAPST Research data includes thousands of people living with ALS including clinical, survival, and longitudinal NfL data Clene plans to analyze the APST ALS NfL biomarker and clinical dataset to compare NfL change from its ongoing NIH-sponsored EAP to address the FDA’s request for supportive evidence of CNM-Au8’s effect on N...
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conf...
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, from 1:10-1:40pm ET. A live webcast of the presentation can be accessed from the Investor Relations sec...
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 ...
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer, will present data from the company’s Expanded Access Program (EAP) evaluating INZ-701 in infants and chi...
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants ...
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates - Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and stabilization or reduction in ectopic calcification and hypophosphatemia, with no radiographic evidence of rickets – - Enrollment complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency; on track to complete dosing in January 2026, with topline data to...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.